ProCE Banner Series

How to Treat CSPC: Current Data, Case Discussion, and Future Perspectives

Join us for this 1-hour CME-certified live Webinar to learn from a urology expert how to optimally care for patients with hormone-sensitive prostate cancer through a series of case discussions across the spectrum of disease.

To Register: To register for the virtual event, please click on the “Learn More” button, next to the date below. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AMA
Who Should Attend

This program is intended for urologists and other healthcare professionals who care for patients with prostate cancer.

All Events

How to Treat CSPC: Current Data, Case Discussion, and Future Perspectives

Past Events

August

17

2023

7:00 PM - 8:00 PM Eastern Time (ET)

Virtual

Topics

  • Welcome and Introduction
  • Case Discussions on Treating CSPC
    • Nonmetastatic CSPC
      • Defining high-risk disease
      • Timing and individualization of ADT
      • Biochemical recurrence
    • Metastatic CSPC
      • De novo vs recurrent disease
      • Low-volume vs high-volume disease
      • GnRH agonists and antagonists
      • MoA, route of administration, efficacy, and toxicities with ADTs
      • Integration of prostate cancer guidelines in patient care
  • Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with castration-sensitive prostate cancer. 

Target Audience
This program is intended for urologists and other healthcare professionals who care for patients with prostate cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Compare the mechanism of action and toxicity profiles associated with luteinizing hormone releasing hormone (LHRH) agonists, gonadotropin-releasing hormone (GnRH) receptor antagonists, and the AR-targeted agents abiraterone acetate, apalutamide, and enzalutamide for castration-sensitive prostate cancer
  • Plan optimal, individualized sequential therapeutic strategies for nonmetastatic or metastatic castration-sensitive prostate cancer, considering all available agents, clinical data, and expert recommendations
  • Apply cardioprotective strategies to reduce risk in patients with prostate cancer receiving ADT
  • Evaluate the clinical potential of investigational therapeutic approaches for patients castration-sensitive prostate cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Myovant Sciences and Pfizer Inc.